Clinical trial · Interventional
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
NCT00370513CI-TRIAL-00030392completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pazopanib | Drug | Pazopanib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pazopanib Arm
- description
- Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
- interventionNames
- Drug: pazopanib
Primary outcomes (1)
- measure
- Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).
- timeFrame
- throughout the study
Secondary outcomes (1)
- measure
- Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans
- timeFrame
- throughout the study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion criteria: * Diagnosis of advanced liver cancer adequate bone marrow, liver and kidney function * Any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study Exclusion criteria: * Pregnant or breastfeeding * Any serious or unstable medical or psychiatric conditions * History of metastases to central nervous system * History of ulcer, inflammatory bowel disease or disease of the gut * History of HIV, or uncontrolled infection * Have had a cardiac condition or stoke during the past 6 months * High blood pressure * Have had a blood clot during the past 6 months * History of bleeding blood vessels
References
Publications (1)
- BACKGROUNDYau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB, Gauvin J, Hodge JP, Dar MM, Poon RT. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011 Nov 1;17(21):6914-23. doi: 10.1158/1078-0432.CCR-11-0793. Epub 2011 Aug 10. PMID 21831954